“Dupixent (ingredient: dupilumab) inhibits the Th2 pathway, which is involved in the Covid-19 cytokine storm. But it does not affect the Th1 pathway required to fight the infection. A majority of atopic dermatitis (AD) patients who were using Dupixent were asymptomatic or had mild symptoms even when they were infected with Covid-19, while many others using immunosuppressants such as cyclosporine had to be hospitalized after the infection.”
Emma Guttman, the co-founder of the International Eczema Council and specialist at the Dermatology and Immunology Department of the Icahn School of Medicine at Mount Sinai Medical Center, said this and other remarks on how to treat AD during the Covid-19 pandemic in a recent interview.
Guttman is a world-renowned expert who discovered the “type 2 inflammation” in the immunological bases of AD, proposed new treatment methods, and opened a new chapter in AD treatment.